Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Cannabinoid Receptor Agonist Market: Competitive Landscape, Pipeline, and Market Analysis 2022
A Cannabinoid Receptor Agonist is a substance that activates the cannabinoid receptors in the body. These receptors are part of the endocannabinoid system, which plays a role in various physiological processes. When a cannabinoid receptor agonist binds to these receptors, it triggers a series of biochemical reactions that modulate neurotransmission and cellular signalling. The mechanism of action of a cannabinoid receptor agonist involves mimicking the effects of endogenous cannabinoids, such as anandamide and 2-arachidonoylglycerol, by binding to and activating the cannabinoid receptors. This activation can lead to a wide range of effects, including pain relief, modulation of appetite, regulation of mood, and immune response modulation. cannabinoid receptor agonists have been studied and used in the treatment of various medical conditions. These include chronic pain, neuropathic pain, spasticity associated with multiple sclerosis, nausea, and vomiting in cancer chemotherapy, appetite stimulation in conditions like HIV/AIDS and cancer, and epilepsy.
The growth drivers of the Cannabinoid Receptor Agonist stimulator market include increasing acceptance of medical cannabis and cannabinoids for therapeutic purposes, as well as the expanding legalization of cannabis in various regions, which opens up new opportunities for research, development, and commercialization of cannabinoid-based medications and treatments. Companies such as Viatris, Jazz, Tetra Bio-Pharma, Ipsen, Alternavida, Avicanna, Axim Biotech, Bausch Health, Bionorica, Botanix Pharma, Cann Pharma, FSD Pharma currently cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, Jazz is one such company that is currently conducting a clinical trial of the drug Cannabidivarin(GWP42006) for the treatment of epilepsy.
Key Developments
In January 2023, Jazz Pharmaceuticals received a NICE recommendation for the reimbursement of Epidyolex® (cannabidiol) for the treatment of Tuberous sclerosis in the UK.
In March 2022, Benuvia Therapeutics pursued 505(b) fast-track approval with the US FDA for Investigational New Drugs for its dronabinol oral solution in Alzheimer's disease.
Approved Cannabinoid Receptor Agonist molecules
Cannabinoid Receptor Agonist Pipeline Molecules
Clinical Activity and Development of Cannabinoid Receptor Agonist
In the cannabinoid receptor agonist space, more than 20 companies are focusing on approximately 94 disease indications and right now about 3520 clinical trials are being conducted in this category of drugs. For instance,
In April 2023, GW Pharmaceuticals presented long-term efficacy and adverse events data from the phase III open-label extension GWPCARE6 trial in tuberous sclerosis at the 75th Annual Meeting of the American Academy of Neurology 2023 (AAN-2023)
In October 2022, Pleo Pharma started a phase II, multicenter, randomized, double-blind, multiple-dose, placebo-controlled clinical trial of two doses of PP-01 (Nabilone & Gabapentin) for the mitigation of cannabis withdrawal symptoms, whose estimated study completion date is September 2023.
ProductName |
Total Studies |
Acetazolamide/tetrahydrocannabinol (IHL-42X) |
6 |
Dronabinol (BX-1) |
6 |
Qixleef (inhaledmedicalcannabis) |
5 |
Cannabidivarin (GWP42006) |
5 |
Dronabinol/palmitoylethanolamide (SCI-110) |
5 |
Micro-palmitoylethanolamide (FSD201) |
4 |
Avi-Dekel (cannabisoil20:1) |
3 |
CannabidiolTechnosphere (cannabidiolinhalationpowder) |
3 |
Syndros (dronabinoloralsolution) |
2 |
Oral delta-9-tetrahydrocannabinol/cannabidiol (oral CBD/THC) |
2 |
BTX-1801 |
1 |
The cannabinoid receptor agonists are primarily used to treat chronic pain, neuropathic pain, spasticity associated with multiple sclerosis, nausea, and vomiting in cancer chemotherapy, appetite stimulation in conditions like HIV/AIDS and cancer, and epilepsy. cannabinoid receptor agonists also help to prevent CNS disorders. For instance, Dronabinol is one drug that is used for CNS disorders in adult patients. In the treatment of neuralgia, sclerosis, nausea, and neurologic manifestations cannabinoid receptor agonist Cesamet(Nabilone) by Viatris is used widely. Through research and development, the indications in which cannabinoid receptor agonists can be used are getting expanded. Trials of Sativex (Nabizimois) are being conducted for the treatment of diseases like squamous cell carcinoma and glioblastoma.
Download Free Sample Report
The approved molecule of cannabinoid receptor agonists is Dronabinol oral, Epidiolex (cannabidiol), Sativex (nabiximols), and Cesamet (nabilone)
The growth drivers of the Cannabinoid Receptor Agonist stimulator market include increasing acceptance of medical cannabis and cannabinoids for therapeutic purposes, as well as the expanding legalization of cannabis in various regions, which opens up new opportunities for research, development, and commercialization of cannabinoid-based medications and treatments
The major players in this space are Tilray, Jazz, Tetra Bio-Pharma, Ipsen, Alternavida, Avicanna, Axim Biotech, and Bausch Health.
The key restraints of the cannabinoid receptor agonist stimulator market include the complexity and variability of allergic diseases, which make it challenging to develop universally effective treatments, and the potential for adverse effects associated with cannabinoid receptor agonist-targeted therapies. Additionally, the high cost of research and development, as well as the regulatory requirements for approval of new therapies, can pose barriers to market entry for cannabinoid receptor agonist stimulators.
Key Market Players